
EquitySector - HealthcareVery High Risk
Regular
NAV (14-Oct-26)
Returns (Since Inception)
Fund Size
₹1,511 Cr
Expense Ratio
2.32%
ISIN
INF277K016A9
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.21%
+11.12% (Cat Avg.)
3 Years
+15.68%
+19.56% (Cat Avg.)
5 Years
+11.69%
+13.08% (Cat Avg.)
10 Years
+12.67%
+14.13% (Cat Avg.)
Since Inception
+11.14%
— (Cat Avg.)
| Equity | ₹1,507.38 Cr | 99.73% |
| Others | ₹4.11 Cr | 0.27% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹120.84 Cr | 7.99% |
| Abbott India Ltd | Equity | ₹89.75 Cr | 5.94% |
| HealthCare Global Enterprises Ltd | Equity | ₹89.52 Cr | 5.92% |
| Divi's Laboratories Ltd | Equity | ₹85.82 Cr | 5.68% |
| Dr Reddy's Laboratories Ltd | Equity | ₹70.32 Cr | 4.65% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹65.9 Cr | 4.36% |
| Rainbow Childrens Medicare Ltd | Equity | ₹65.07 Cr | 4.30% |
| Cipla Ltd | Equity | ₹63.78 Cr | 4.22% |
| Torrent Pharmaceuticals Ltd | Equity | ₹56.88 Cr | 3.76% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹56.09 Cr | 3.71% |
| Lupin Ltd | Equity | ₹47.4 Cr | 3.14% |
| Bayer CropScience Ltd | Equity | ₹44.69 Cr | 2.96% |
| Syngene International Ltd | Equity | ₹43.1 Cr | 2.85% |
| Procter & Gamble Health Ltd | Equity | ₹41.5 Cr | 2.75% |
| Sai Life Sciences Ltd | Equity | ₹39.34 Cr | 2.60% |
| PI Industries Ltd | Equity | ₹39.16 Cr | 2.59% |
| Anthem Biosciences Ltd | Equity | ₹38.89 Cr | 2.57% |
| Pfizer Ltd | Equity | ₹37.85 Cr | 2.50% |
| Alkem Laboratories Ltd | Equity | ₹35.66 Cr | 2.36% |
| FDC Ltd | Equity | ₹33.84 Cr | 2.24% |
| Fortis Healthcare Ltd | Equity | ₹29.49 Cr | 1.95% |
| Acutaas Chemicals Ltd | Equity | ₹29.44 Cr | 1.95% |
| Dr. Lal PathLabs Ltd | Equity | ₹26.67 Cr | 1.76% |
| Aster DM Quality Care Ltd Ordinary Shares | Equity | ₹25.27 Cr | 1.67% |
| Ajanta Pharma Ltd | Equity | ₹24.64 Cr | 1.63% |
| Natco Pharma Ltd | Equity | ₹22.77 Cr | 1.51% |
| Sumitomo Chemical India Ltd Ordinary Shares | Equity | ₹20.79 Cr | 1.38% |
| Gillette India Ltd | Equity | ₹18.57 Cr | 1.23% |
| Navin Fluorine International Ltd | Equity | ₹17.79 Cr | 1.18% |
| Ipca Laboratories Ltd | Equity | ₹13.79 Cr | 0.91% |
| Prasol Chemicals Ltd | Equity | ₹13.28 Cr | 0.88% |
| Symbiotec Pharmalab Ltd | Equity | ₹13.21 Cr | 0.87% |
| Mankind Pharma Ltd | Equity | ₹11.58 Cr | 0.77% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹11.55 Cr | 0.76% |
| Biocon Ltd | Equity | ₹10.36 Cr | 0.69% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹10.32 Cr | 0.68% |
| Manipal Health Enterprises Ltd | Equity | ₹8.98 Cr | 0.59% |
| Zim Laboratories Ltd Ordinary Shares | Equity | ₹8.71 Cr | 0.58% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹8.67 Cr | 0.57% |
| Molbio Diagnostics Ltd | Equity | ₹8.11 Cr | 0.54% |
| Gujarat Fluorochemicals Ltd Ordinary Shares | Equity | ₹8 Cr | 0.53% |
| I) Repo | Cash - Repurchase Agreement | ₹2.84 Cr | 0.19% |
| Cash / Net Current Asset | Cash | ₹1.27 Cr | 0.08% |
| Jubilant Pharmova Ltd | Equity | ₹0.01 Cr | 0.00% |
Large Cap Stocks
26.02%
Mid Cap Stocks
33.87%
Small Cap Stocks
36.96%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,315.65 Cr | 87.04% |
| Basic Materials | ₹173.15 Cr | 11.46% |
| Consumer Defensive | ₹18.57 Cr | 1.23% |
Standard Deviation
This fund
16.71%
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
0.65
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better
Since September 2024
ISIN INF277K016A9 | Expense Ratio 2.32% | Exit Load No Charges | Fund Size ₹1,511 Cr | Age 10 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹2,41,427 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments